|
Marknaden stängd -
Andra börsplatser
|
5-dagars förändring | Förändring 1 jan. | ||
| 282,55 DKK | −0,19 % |
|
−0,46 % | −13,13 % |
| 06-11 | Brittiska myndigheter godkänner Novo Nordisks viktminskningspiller | MT |
| 06-11 | Novo Nordisk får brittiskt godkännande för Wegovy i tablettform | MT |
| Skatteperiod: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Lönsamhet | ||||||||||
Return on Assets | 21,85 | 21,69 | 23,39 | 22,41 | 17,43 | |||||
Return on Total Capital | 43,36 | 45,74 | 53,53 | 46,03 | 30,77 | |||||
Return On Equity % | 71,24 | 72 | 88,07 | 80,78 | 60,7 | |||||
Return on Common Equity | 71,24 | 72 | 88,07 | 80,78 | 60,7 | |||||
Marginalanalys | ||||||||||
Gross Profit Margin % | 83,2 | 83,92 | 84,6 | 85 | 82,41 | |||||
SG&A Margin | 29,16 | 28,64 | 26,52 | 23,2 | 21,96 | |||||
EBITDA Margin % | 45,14 | 45,73 | 47,28 | 50,51 | 49,6 | |||||
EBITA Margin % | 42,76 | 43,53 | 45,47 | 48,94 | 47,51 | |||||
EBIT Margin % | 42,15 | 42,73 | 44,77 | 48,17 | 45,5 | |||||
Income From Continuing Operations Margin % | 33,92 | 31,38 | 36,03 | 34,78 | 33,14 | |||||
Net Income Margin % | 33,92 | 31,38 | 36,03 | 34,78 | 33,14 | |||||
Net Avail. For Common Margin % | 33,92 | 31,38 | 36,03 | 34,78 | 33,14 | |||||
Normalized Net Income Margin | 26,4 | 24,89 | 28,54 | 29,86 | 29 | |||||
Levered Free Cash Flow Margin | 31,13 | 32,49 | 23,29 | 21,35 | 0,12 | |||||
Unlevered Free Cash Flow Margin | 31,26 | 32,63 | 23,44 | 21,7 | 0,97 | |||||
Tillgångsomslutning | ||||||||||
Asset Turnover | 0,83 | 0,81 | 0,84 | 0,74 | 0,61 | |||||
Fixed Assets Turnover | 2,67 | 2,9 | 2,95 | 2,29 | 1,67 | |||||
Receivables Turnover (Average Receivables) | 4,12 | 3,88 | 4,03 | 4,25 | 4,33 | |||||
Inventory Turnover (Average Inventory) | 1,24 | 1,29 | 1,27 | 1,2 | 1,2 | |||||
Kortfristig likviditet | ||||||||||
Current Ratio | 0,86 | 0,89 | 0,82 | 0,74 | 0,8 | |||||
Quick Ratio | 0,65 | 0,67 | 0,62 | 0,52 | 0,54 | |||||
Operating Cash Flow to Current Liabilities | 0,55 | 0,65 | 0,64 | 0,56 | 0,55 | |||||
Days Sales Outstanding (Average Receivables) | 88,63 | 94,06 | 90,62 | 86,15 | 84,33 | |||||
Days Outstanding Inventory (Average Inventory) | 294,35 | 282,33 | 286,77 | 305,25 | 303,64 | |||||
Average Days Payable Outstanding | 107,59 | 134,38 | 174,07 | 189,45 | 106,63 | |||||
Cash Conversion Cycle (Average Days) | 275,38 | 242,01 | 203,32 | 201,96 | 281,34 | |||||
Långsiktig solvens | ||||||||||
Total Debt/Equity | 37,66 | 30,88 | 25,34 | 71,64 | 67,49 | |||||
Total Debt / Total Capital | 27,36 | 23,6 | 20,22 | 41,74 | 40,29 | |||||
LT Debt/Equity | 18,32 | 29,13 | 19,26 | 62,5 | 61,29 | |||||
Long-Term Debt / Total Capital | 13,31 | 22,25 | 15,37 | 36,41 | 36,6 | |||||
Total Liabilities / Total Assets | 63,63 | 65,4 | 66,12 | 69,2 | 64,26 | |||||
EBIT / Interest Expense | 205,33 | 200,05 | 191,86 | 85,29 | 33,42 | |||||
EBITDA / Interest Expense | 223,02 | 216,87 | 204,92 | 90,35 | 36,84 | |||||
(EBITDA - Capex) / Interest Expense | 201,1 | 184,74 | 157,3 | 61,59 | 22,54 | |||||
Total Debt / EBITDA | 0,41 | 0,31 | 0,24 | 0,69 | 0,85 | |||||
Net Debt / EBITDA | 0,14 | 0,03 | −0,03 | 0,52 | 0,67 | |||||
Total Debt / (EBITDA - Capex) | 0,46 | 0,37 | 0,32 | 1,02 | 1,38 | |||||
Net Debt / (EBITDA - Capex) | 0,16 | 0,03 | −0,04 | 0,76 | 1,1 | |||||
Tillväxt jämfört med föregående år | ||||||||||
Total Revenues, 1 Yr. Growth % | 10,91 | 25,68 | 31,26 | 25,03 | 6,43 | |||||
Gross Profit, 1 Yr. Growth % | 10,5 | 26,77 | 32,32 | 25,34 | 3,18 | |||||
EBITDA, 1 Yr. Growth % | 8,49 | 27,34 | 35,78 | 32,7 | 5,22 | |||||
EBITA, 1 Yr. Growth % | 8,75 | 27,93 | 37,2 | 33,69 | 4,02 | |||||
EBIT, 1 Yr. Growth % | 8,93 | 27,43 | 37,61 | 33,6 | 1,24 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 13,33 | 16,27 | 50,71 | 20,68 | 1,43 | |||||
Net Income, 1 Yr. Growth % | 13,33 | 16,27 | 50,71 | 20,68 | 1,43 | |||||
Normalized Net Income, 1 Yr. Growth % | 10,82 | 18,46 | 50,62 | 29,96 | 4,11 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 15,16 | 17,84 | 52,37 | 21,54 | 1,77 | |||||
Accounts Receivable, 1 Yr. Growth % | 46,55 | 24,4 | 28,11 | 11,08 | −1,52 | |||||
Inventory, 1 Yr. Growth % | 5,85 | 24,3 | 30,44 | 28,41 | 21,48 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 10,13 | 20,43 | 36,43 | 78,63 | 28,88 | |||||
Total Assets, 1 Yr. Growth % | 34,22 | 24,03 | 30,35 | 48,11 | 16,6 | |||||
Tangible Book Value, 1 Yr. Growth % | −35,37 | 16,3 | 41,81 | −29,81 | 95,91 | |||||
Common Equity, 1 Yr. Growth % | 11,72 | 18,01 | 27,64 | 34,65 | 35,24 | |||||
Cash From Operations, 1 Yr. Growth % | 5,87 | 43,43 | 38,06 | 11,07 | −1,54 | |||||
Capital Expenditures, 1 Yr. Growth % | 8,76 | 91,73 | 112,46 | 82,76 | 27,51 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 157 | 31,17 | −5,85 | 13,64 | −99,38 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 154,42 | 31,17 | −5,65 | 14,81 | −95,12 | |||||
Dividend Per Share, 1 Yr. Growth % | 14,29 | 19,23 | 51,61 | 21,28 | 2,63 | |||||
Sammansatt Årlig Tillväxthastighet Över Två År | ||||||||||
Total Revenues, 2 Yr. CAGR % | 7,42 | 18,06 | 28,44 | 28,11 | 15,35 | |||||
Gross Profit, 2 Yr. CAGR % | 7,2 | 18,36 | 29,52 | 28,91 | 13,72 | |||||
EBITDA, 2 Yr. CAGR % | 6,24 | 17,55 | 31,23 | 34,46 | 17,66 | |||||
EBITA, 2 Yr. CAGR % | 6,61 | 18,1 | 32,36 | 35,67 | 17,4 | |||||
EBIT, 2 Yr. CAGR % | 6,33 | 18,2 | 32,52 | 36,01 | 15,89 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 10,73 | 14,79 | 32,37 | 34,86 | 10,64 | |||||
Net Income, 2 Yr. CAGR % | 10,73 | 14,79 | 32,37 | 34,86 | 10,64 | |||||
Normalized Net Income, 2 Yr. CAGR % | 10,52 | 14,95 | 33,67 | 40,33 | 15,91 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 12,52 | 16,49 | 34 | 36,08 | 11,21 | |||||
Accounts Receivable, 2 Yr. CAGR % | 27,73 | 35,02 | 26,24 | 19,29 | 4,59 | |||||
Inventory, 2 Yr. CAGR % | 5,46 | 14,7 | 27,33 | 29,42 | 24,9 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 4,65 | 15,16 | 28,18 | 56,11 | 51,36 | |||||
Total Assets, 2 Yr. CAGR % | 24,44 | 29,02 | 27,15 | 38,95 | 31,39 | |||||
Tangible Book Value, 2 Yr. CAGR % | −27,01 | −13,3 | 29,38 | −0,23 | 17,75 | |||||
Common Equity, 2 Yr. CAGR % | 10,83 | 14,82 | 22,73 | 31,1 | 34,94 | |||||
Cash From Operations, 2 Yr. CAGR % | 8,43 | 23,23 | 40,72 | 23,83 | 4,58 | |||||
Capital Expenditures, 2 Yr. CAGR % | −15,78 | 44,4 | 101,83 | 97,06 | 52,66 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 27,93 | 84,1 | 11,02 | 3,83 | −91,69 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 27,86 | 83,17 | 11,14 | 4,47 | −76,6 | |||||
Dividend Per Share, 2 Yr. CAGR % | 11,6 | 16,73 | 34,45 | 35,6 | 11,57 | |||||
Treårig Sammansatt Årlig Tillväxthastighet | ||||||||||
Total Revenues, 3 Yr. CAGR % | 7,98 | 13,19 | 22,31 | 27,29 | 20,43 | |||||
Gross Profit, 3 Yr. CAGR % | 7,53 | 13,36 | 22,84 | 28,2 | 19,69 | |||||
EBITDA, 3 Yr. CAGR % | 7,49 | 12,85 | 23,31 | 32 | 23,63 | |||||
EBITA, 3 Yr. CAGR % | 8,41 | 13,29 | 24,13 | 33,1 | 23,89 | |||||
EBIT, 3 Yr. CAGR % | 7,89 | 12,95 | 24,32 | 33,18 | 22,97 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 7,33 | 12,54 | 25,7 | 28,35 | 22,65 | |||||
Net Income, 3 Yr. CAGR % | 7,33 | 12,54 | 25,7 | 28,35 | 22,65 | |||||
Normalized Net Income, 3 Yr. CAGR % | 7,82 | 13,1 | 25,76 | 32,71 | 26,74 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 9,19 | 14,27 | 27,4 | 29,71 | 23,52 | |||||
Accounts Receivable, 3 Yr. CAGR % | 21,28 | 26,61 | 32,67 | 20,97 | 11,91 | |||||
Inventory, 3 Yr. CAGR % | 6,3 | 11,4 | 19,73 | 27,69 | 26,72 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 9,74 | 9,67 | 21,86 | 43,18 | 46,21 | |||||
Total Assets, 3 Yr. CAGR % | 20,64 | 24,3 | 29,47 | 33,79 | 31,04 | |||||
Tangible Book Value, 3 Yr. CAGR % | −16,1 | −14,75 | 2,65 | 5,52 | 25,28 | |||||
Common Equity, 3 Yr. CAGR % | 10,92 | 13,17 | 18,94 | 26,58 | 32,46 | |||||
Cash From Operations, 3 Yr. CAGR % | 7,22 | 19,03 | 27,98 | 30,05 | 14,72 | |||||
Capital Expenditures, 3 Yr. CAGR % | −13,05 | 10,79 | 64,24 | 95,26 | 70,44 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 16,82 | 29 | 47,2 | 12,19 | −81,29 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 16,91 | 28,96 | 46,8 | 12,65 | −62,66 | |||||
Dividend Per Share, 3 Yr. CAGR % | 8,47 | 14,09 | 27,36 | 29,91 | 23,58 | |||||
Sammansatt Årlig Tillväxthastighet Över Fem År | ||||||||||
Total Revenues, 5 Yr. CAGR % | 4,72 | 9,64 | 15,74 | 18,94 | 19,48 | |||||
Gross Profit, 5 Yr. CAGR % | 4,37 | 9,56 | 15,84 | 19,35 | 19,16 | |||||
EBITDA, 5 Yr. CAGR % | 4,24 | 9,19 | 16,5 | 21,1 | 21,22 | |||||
EBITA, 5 Yr. CAGR % | 4,27 | 9,48 | 17,45 | 21,82 | 21,6 | |||||
EBIT, 5 Yr. CAGR % | 4,15 | 9,08 | 17,09 | 21,66 | 21,04 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 4,72 | 7,81 | 16,72 | 20,99 | 19,44 | |||||
Net Income, 5 Yr. CAGR % | 4,72 | 7,81 | 16,72 | 20,99 | 19,44 | |||||
Normalized Net Income, 5 Yr. CAGR % | 4,48 | 7,66 | 17,45 | 23,29 | 21,88 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 6,75 | 9,69 | 18,51 | 22,54 | 20,66 | |||||
Accounts Receivable, 5 Yr. CAGR % | 14,97 | 20,18 | 23,24 | 23,63 | 20,63 | |||||
Inventory, 5 Yr. CAGR % | 6,47 | 9,67 | 14,26 | 18,29 | 21,77 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 12,9 | 13,6 | 16,77 | 26,3 | 32,9 | |||||
Total Assets, 5 Yr. CAGR % | 14,8 | 18,71 | 23,21 | 29,97 | 30,23 | |||||
Tangible Book Value, 5 Yr. CAGR % | −8,31 | −7,16 | −0,23 | −8,95 | 8,44 | |||||
Common Equity, 5 Yr. CAGR % | 9,34 | 10,88 | 15,5 | 20,03 | 25,1 | |||||
Cash From Operations, 5 Yr. CAGR % | 2,63 | 13,89 | 19,54 | 20,93 | 18,05 | |||||
Capital Expenditures, 5 Yr. CAGR % | −2,17 | 9,76 | 21,78 | 39,49 | 59,5 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 8,96 | 21,89 | 14,5 | 18,27 | −53,3 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 9,02 | 21,93 | 14,6 | 18,54 | −29,46 | |||||
Dividend Per Share, 5 Yr. CAGR % | 6,47 | 9,57 | 18,2 | 22,25 | 20,79 |
- Börsen
- Aktier
- NOVO B Aktie
- Finanser Novo Nordisk A/S
- Finansiella nyckeltal
Välj din utgåva
All finansiell information anpassad till den nationella nivån
MarketScreener is also available in this country: United States.
Switch edition















